Berman Capital Advisors’s Nektar Therapeutics NKTR Stock Holding History

Berman Capital Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$40K	Buy	149 +145	+3,625%	+$34.9K	0.01%	765
2021 Q2	$0	Buy	+4	New	+$1.11K	﹤0.01%	1987
2020 Q1	–	Sell	-8	Closed	-$2K	–	1600
2019 Q4	$2K	Buy	+8	New	+$2.32K	﹤0.01%	1222
2019 Q3	–	Sell	-7	Closed	-$3K	–	1533
2019 Q2	$3K	Buy	+7	New	+$3.51K	﹤0.01%	1109
2019 Q1	–	Sell	-6	Closed	-$2K	–	1430
2018 Q4	$2K	Buy	+6	New	+$3.62K	﹤0.01%	884

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Berman Capital Advisors's NKTR Position: Q3 2021 in Review

Berman Capital Advisors increased its Nektar Therapeutics (NKTR) stake by 3,625% in Q3 2021, buying an estimated $34.9K and bringing the position to 149 shares worth $40K. The position accounts for 0.01% of the portfolio, ranked #765.

Berman Capital Advisors first reported a position in NKTR in Q4 2018 and has held it in 5 quarters since. 241 funds tracked by Wall St. Rank hold NKTR as of Q3 2021.

Berman Capital Advisors held 149 shares of Nektar Therapeutics worth $40K as of Q3 2021.
Berman Capital Advisors bought 145 Nektar Therapeutics shares in Q3 2021, an estimated $34.9K.
Nektar Therapeutics made up 0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #765 holding.
Berman Capital Advisors first reported a position in Nektar Therapeutics in Q4 2018 and has held it in 5 quarters since.
241 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.